Ray Therapeutics Closes $125M Series B to Advance Vision‑Restoring Therapies

Why It Matters

The wave of multi‑hundred‑million investments signals strong market confidence in next‑generation biotech modalities—optogenetics, licensed neurology assets, modified DNA and AI platforms—potentially shortening development timelines and expanding therapeutic options.

Key Takeaways

• Ray Therapeutics' $125M Series B targets RP, Stargardt, GA.
• Tortugas raises $106M to fast‑track schizophrenia and tinnitus candidates.
• Serif Bio receives $50M for “modified DNA” therapy platform.
• Alloy’s $40M Series E pushes valuation past $1B.
• Investors diversify into optogenetics, neurology, AI, and gene‑editing technologies.

Pulse Analysis

Ray Therapeutics' latest $125 million raise underscores the growing commercial appeal of optogenetic approaches for ocular disease. By delivering light‑sensitive proteins directly to retinal ganglion cells, the company hopes to restore vision in conditions that currently lack effective treatments. The funding not only fuels Phase 1 and Phase 2 trials for RTx‑015 and RTx‑021 but also positions Ray as a potential acquisition target for larger ophthalmic players seeking to augment their pipelines with gene‑based modalities.

Tortugas Neuroscience illustrates a different financing model: leveraging licensed assets from established Asian pharma to accelerate U.S. development. With $106 million, the startup can move two mid‑stage candidates—one for schizophrenia, another for tinnitus—into Phase 2, de‑risking the programs before broader market entry. This strategy reflects a broader trend where U.S. biotech firms partner with overseas innovators to tap into novel mechanisms while offering investors exposure to diversified neurology portfolios.

The simultaneous launches of Serif Biomedicines and Alloy Therapeutics highlight investor appetite for platform technologies that promise scalability. Serif’s "modified DNA" platform aims to combine the durability of gene therapy with the safety and re‑dosing flexibility of mRNA, targeting rare diseases where conventional approaches fall short. Meanwhile, Alloy’s AI‑driven ecosystem, now valued over $1 billion after a $40 million Series E, provides computational tools that accelerate antibody, bispecific and cell‑therapy discovery for more than 200 partners. Together, these deals signal a shift toward capital‑intensive, technology‑centric biotech ventures that could reshape drug development economics in the coming decade.

Deal Summary

Berkeley‑based Ray Therapeutics, which develops optogenetic eye‑disorder therapies, closed a $125 million Series B round. The financing was led by Janus Henderson Investors with participation from Adage Capital Management, Franklin Templeton, Invus, Marshall Wace and the venture arms of MSD and Novo Nordisk. The capital will fund clinical trials for its lead candidates RTx‑015 and RTx‑021 targeting retinitis pigmentosa, Stargardt disease and geographic atrophy.